Marker Therapeutics (MRKR) Short term Debt (2010 - 2022)
Marker Therapeutics (MRKR) posted quarterly Short term Debt of $2.5 million for Q4 2022, down 50.5% quarter-over-quarter from $5.0 million in Q3 2022.
Marker Therapeutics (MRKR) Short term Debt (2010 - 2022) Analysis & Trends
Marker Therapeutics (MRKR) has reported Short term Debt for 6 consecutive years, with $2.5 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Short term Debt changed N/A year-over-year to $2.5 million; the TTM figure through Dec 2022 stood at $2.5 million (changed N/A YoY), while the FY2022 annual figure was $2.5 million, changed N/A from the prior year.
- Short term Debt eased to $2.5 million in Q4 2022 per MRKR's latest filing, from $5.0 million in the prior quarter.
- Across five years, Short term Debt topped out at $8.0 million in Q2 2022 and bottomed at $2.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - |
| 10 | Marker Therapeutics | 26.65 Mn | 14.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 5.05 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2014 | 81,000.00 |
| Dec 31, 2013 | 369,346.00 |
| Sep 30, 2013 | 10,000.00 |
| Mar 31, 2013 | 153,846.00 |
| Dec 31, 2012 | 10,000.00 |
| Sep 30, 2012 | 28,000.00 |
| Jun 30, 2012 | 220,698.00 |
| Mar 31, 2012 | 293,805.00 |
| Dec 31, 2011 | 7,000.00 |
| Sep 30, 2011 | 7,000.00 |
| Jun 30, 2011 | 100,000.00 |
| Dec 31, 2010 | 259,305.00 |